Innovative approaches offer the potential for effective treatments to limited target areas with improved side effect profiles.
A phase 3 trial has found pazopanib (Votrient) and sunitinib (Sutent) are both equally effective for treating metastatic kidney cancer.
Recent studies provide persuasive evidence that the majority of small renal masses will grow slowly over time.
Patients with blood group O have a lower risk of lymph node metastases but a higher risk of bilateral disease.
Patients aged 75-79 who had localized tumors had worse cancer-specific survival with nonsurgical management than surgery.
Patients with this malignancy had a 73% prevalence of simple renal cysts.
Only 9.5% of the study participants were told about the possibilities of overdiagnosis and overtreatment by their physicians.
Most want to be told of screening harms, but only 9.5 percent informed about overdiagnosis, overtx.
Recurrence that occurs more than 48 months after surgery is no longer significantly associated with reduced survival from renal cell carcinoma.
Researchers observe a high rate of local disease control with increased progression-free survival.
It improves predictions of perioperative complication risks, according to researchers.
In a head-to-head trial, patients had similar progression-free survival with pazopanib and sunitinib, but experienced fewer adverse effects.
Renal cancers were found in 5% of patients with autosomal dominant polycystic kidney disease.
The beneficial impact of this approach on renal function does not improve survival, however.
Highest intake found to increase the risk of renal pelvis and ureter cancers 11-fold.
Bone metastases shorten progression-free and overall survival, study finds.
Compared with radical nephrectomy, nephron-sparing surgery shift serum creatinine downward.
Study demonstrates improved disease-specific and overall survival.
